These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7300363)

  • 1. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy.
    Hortobagyi GN; Blumenschein GR; Buzdar AU; Yap HY; Schell FC; Barnes BC; Burgess MA
    J Surg Oncol; 1981; 18(2):163-72. PubMed ID: 7300363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
    Hortobagyi GN; Gutterman JU; Blumenschein GR; Tashima CK; Burgess MA; Einhorn L; Buzdar AU; Richman SP; Hersh EM
    Cancer; 1979 Apr; 43(4):1225-33. PubMed ID: 445325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin.
    Hortobagyi GN; Yap HY; Blumenschein GR; Gutterman JU; Buzdar AU; Tashima CK; Hersh EM
    Cancer Treat Rep; 1978 Nov; 62(11):1685-92. PubMed ID: 728894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole.
    Hortobagyi GN; Gutterman JU; Blumenschein GR; Yap HY; Buzdar AU; Tashima CK; Burgess MA; Hersh EM
    Cancer; 1979 Mar; 43(3):1112-22. PubMed ID: 427716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
    Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
    Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
    Hortobagyi GN; Gutterman JU; Blumenschein GR; Tashima CK; Burgess MA; Einhorn L; Buzdar AU; Richman SP; Hersh EM
    Cancer; 1979 Nov; 44(5):1955-62. PubMed ID: 387212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.
    Gutterman JU; Cardenas JO; Blumenschein GR; Hortobagyi G; Burgess MA; Livingston RB; Mavligit GM; Freireich EJ; Gottlieb JA; Hersh EM
    Br Med J; 1976 Nov; 2(6046):1222-5. PubMed ID: 791447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
    J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy.
    Hortobagyi GN; Spanos W; Montague ED; Buzdar AU; Yap HY; Blumenschein GR
    Int J Radiat Oncol Biol Phys; 1983 May; 9(5):643-50. PubMed ID: 6343312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer.
    Hortobagyi GN; Blumenschein GR; Tashima CK; Buzdar AU; Burgess MA; Livingston RB; Valdivieso M; Gutterman JU; Hersh EM; Bodey GP
    Cancer; 1979 Aug; 44(2):398-405. PubMed ID: 383255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).
    Buzdar AU; Blumenschein GR; Smith TL; Tashima CK; Hortobagyi GN; Yap HY; Gutterman JU; Hersh EM; Gehan EA
    J Surg Oncol; 1979; 12(1):27-40. PubMed ID: 480951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
    Henderson IC; Gelman R; Canellos GP; Frei E
    Cancer Treat Rep; 1981; 65 Suppl 1():67-75. PubMed ID: 6976832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma.
    Krutchik AN; Buzdar AU; Blumenschein GR; Hortobagyi GN; Tashima CK; Gutterman JU; Yap HY; Hersh EM
    J Surg Oncol; 1979; 11(4):325-32. PubMed ID: 109703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
    Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer.
    Papadimitriou CA; Dimopoulos MA; Ampela C; Louvrou-Fertaki A; Anagnostopoulos A; Athanassiades P; Stamatelopoulos S; Keramopoulos A
    Oncology; 1998; 55(6):533-7. PubMed ID: 9778619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma.
    Blumenschein GR; Hortobagyi GN; Richman SP; Gutterman JU; Tashima CK; Buzdar AU; Burgess MA; Livingston RB; Hersh EM
    Cancer; 1980 Feb; 45(4):742-9. PubMed ID: 6986970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
    Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
    J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
    Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
    Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.